Novo Nordisk is maintaining its position as a strong competitor in the obesity drug market, contrary to views that it is losing to Eli Lilly. The company is expanding manufacturing capabilities, developing next-generation therapies like CagriSema, and leveraging its pricing and direct-to-consumer strategies. Trading at a discount compared to peers, Novo Nordisk shows strong fundamentals and growth potential. Analysts rate it a Buy with a 2030 price target of $135–$165, supported by stable insulin and GLP-1 franchises and strategic execution.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
